The successful introduction of the tyrosine kinase inhibitors has initiated a new era in the
management of chronic myeloid leukemia (CML). Imatinib mesilate therapy has significantly …

Dasatinib is a novel, potent, multi-targeted kinase inhibitor that is approved in Philadelphia
chromosome positive (Ph+) chronic myelogenous leukemia (CML) and Ph+ acute …

Myeloid hematological malignancies are among the epigenetically best characterized
neoplasms. The comparatively low number of recurring balanced and unbalanced …

Centrosomes play fundamental roles in mitotic spindle organization, chromosome
segregation and maintenance of genetic stability. Recently, we have shown that centrosome …

Protection of the transcriptional “stemness” network is important to maintain a healthy
hematopoietic stem cells (HSCs) compartment during the lifetime of the organism. Recent …

The introduction of imatinib, a tyrosine kinase inhibitor (TKI) that targets the BCR-ABL
protein, has revolutionised the treatment of chronic myeloid leukaemia (CML), producing …

The vast majority of patients with chronic myelogeneous leukemia (CML)(> 95%) has a
breakpoint in the M-bcr, resulting in b3-a2, b2-a3, b2-a2 or b3-a3 fusion gene transcripts …

Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal bone marrow (BM)
disorders characterized by the presence of dysplastic maturation of hematopoietic cells …

Earlier use of more potent tyrosine kinase inhibitors such as dasatinib improves response
rates for patients with chronic myeloid leukemia (CML). The SRC–ABL Tyrosine Kinase …

Of the myeloproliferative/myelodysplastic disorders (MPD/MDS) that occur in childhood
most, regarding the cytogenetic and molecular genetic basis, is known about the two purely …